<DOC>
	<DOC>NCT02305238</DOC>
	<brief_summary>To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) . To assess the safety of IVT administration of aflibercept with two different approaches of Treat and Extend dosing regimen in Japanese subjects with wAMD for up to 2 years.</brief_summary>
	<brief_title>Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Japanese men and women ≥ 50 years of age Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD, including juxtafoveal lesions that affect the fovea as evidenced by fluorescein angiography (FA) in the study eye Early Treatment Diabetic Retinopathy Study (ETDRS) bestcorrected visual acuity (BCVA) of 73 to 25 letters (approximately 20/40 to 20/320 at Snellen equivalent) in the study eye Prior treatment of the study eye with intraocular antiVEGF(Vascular Endothelial Growth Factor) agents, verteporfin photodynamic therapy (PDT), other laser, intraocular corticosteroids, surgical interventions (except cataract surgery more than 30 days prior to screening) or systemic use of antiVEGF products within 3 months prior to study entry Active or suspected infection in or surrounding of the study eye Active severe intraocular inflammation in the study eye Intraocular pressure (IOP) ≥ 25 mmHg in the study eye Ocular condition in the study eye which may impact vision and confound study outcomes</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Eylea,</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Treat and Extend regimen</keyword>
	<keyword>Age-related macular degeneration</keyword>
</DOC>